102 related articles for article (PubMed ID: 26739927)
1. Reply to Comment on: Treatment of EBV-Associated Nodular Sclerosing Hodgkin Lymphoma in a Patient With Ataxia Telangiectasia With Brentuximab Vedotin and Reduced COPP Plus Rituximab.
Meister MT; Voss S; Schwabe D
Pediatr Blood Cancer; 2016 May; 63(5):947. PubMed ID: 26739927
[No Abstract] [Full Text] [Related]
2. Comment on: Treatment of EBV-Associated Nodular Sclerosing Hodgkin Lymphoma in a Patient With Ataxia Telangiectasia With Brentuximab Vedotin and Reduced COPP Plus Rituximab.
Zielen S
Pediatr Blood Cancer; 2016 May; 63(5):946. PubMed ID: 26719151
[No Abstract] [Full Text] [Related]
3. Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab.
Meister MT; Voss S; Schwabe D
Pediatr Blood Cancer; 2015 Nov; 62(11):2018-20. PubMed ID: 26109475
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma.
Tse E; Au-Yeung R; Chau D; Hwang YY; Loong F; Kwong YL
Ann Hematol; 2022 May; 101(5):1149-1152. PubMed ID: 34757467
[No Abstract] [Full Text] [Related]
5. Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine.
Poon LM; Kwong YL
Ann Hematol; 2016 Apr; 95(5):847-9. PubMed ID: 26931114
[No Abstract] [Full Text] [Related]
6. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
7. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
8. Synchronous Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly and Epstein-Barr virus-positive classical Hodgkin lymphoma.
Hwang YY; Leung AY; Lau WH; Loong F; So JC; Tse E; Kwong YL
Histopathology; 2011 Aug; 59(2):352-5. PubMed ID: 21884219
[No Abstract] [Full Text] [Related]
9. Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab.
Muroi K; Sakata-Yanagimoto M; Sato T; Yokoyama Y; Maie K; Kurita N; Obara N; Hasegawa Y; Noguchi M; Chiba S
Ann Hematol; 2015 Dec; 94(12):2061-2. PubMed ID: 26240012
[No Abstract] [Full Text] [Related]
10. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
Kalac M; Lue JK; Lichtenstein E; Turenne I; Rojas C; Amengual JE; Sawas A; Deng C; Mapara MY; Connors JM; Kuruvilla J; O'Connor OA
Br J Haematol; 2018 Mar; 180(5):757-760. PubMed ID: 27984643
[No Abstract] [Full Text] [Related]
12. Epstein-barr virus-associated extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma) arising in the parotid gland of a child with ataxia telangiectasia.
Bennett JA; Bayerl MG
J Pediatr Hematol Oncol; 2015 Mar; 37(2):e114-7. PubMed ID: 25692616
[TBL] [Abstract][Full Text] [Related]
13. Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights.
Papageorgiou SG; Tsiodras S; Siakallis G; Bazani E; Spathis A; Poulakou G; Korkolopoulou P; Panayiotides I; Pappa V
Pathol Res Pract; 2016 Dec; 212(12):1194-1198. PubMed ID: 28340951
[TBL] [Abstract][Full Text] [Related]
14. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
[TBL] [Abstract][Full Text] [Related]
15. EBV DNA: a Hodgkin lymphoma biomarker?
Meyer RM
Blood; 2013 May; 121(18):3541-2. PubMed ID: 23640993
[TBL] [Abstract][Full Text] [Related]
16. [Sequential monitoring of plasma EBV-DNA level in a patient with EBV-positive Hodgkin lymphoma].
Uchida E; Honma R; Igarashi A; Kurata M; Imadome K; Omoto E; Miura O; Arai A
Rinsho Ketsueki; 2012 Jan; 53(1):87-91. PubMed ID: 22374530
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas.
Kim M; Lee JO; Koh J; Kim TM; Lee JY; Jeon YK; Keam B; Kim DW; Lee JS; Heo DS
Haematologica; 2021 Aug; 106(8):2277-2280. PubMed ID: 33792222
[No Abstract] [Full Text] [Related]
18. Complete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma.
O'Sullivan CC; Ozdemirli M; Bazylewicz M; Cheson BD
Clin Adv Hematol Oncol; 2013 Jun; 11(6):382-5. PubMed ID: 24472809
[No Abstract] [Full Text] [Related]
19. Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):15-8. PubMed ID: 25768997
[No Abstract] [Full Text] [Related]
20. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma.
Hohaus S; Santangelo R; Giachelia M; Vannata B; Massini G; Cuccaro A; Martini M; Cesarini V; Cenci T; D'Alo F; Voso MT; Fadda G; Leone G; Larocca LM
Clin Cancer Res; 2011 May; 17(9):2885-92. PubMed ID: 21478335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
